CN118516248A - Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide - Google Patents
Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide Download PDFInfo
- Publication number
- CN118516248A CN118516248A CN202410307103.6A CN202410307103A CN118516248A CN 118516248 A CN118516248 A CN 118516248A CN 202410307103 A CN202410307103 A CN 202410307103A CN 118516248 A CN118516248 A CN 118516248A
- Authority
- CN
- China
- Prior art keywords
- product
- bifidobacterium animalis
- bifidobacterium
- subspecies
- animalis subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 48
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 230000002411 adverse Effects 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 18
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 14
- 206010028813 Nausea Diseases 0.000 claims abstract description 13
- 206010047700 Vomiting Diseases 0.000 claims abstract description 13
- 230000008693 nausea Effects 0.000 claims abstract description 13
- 230000008673 vomiting Effects 0.000 claims abstract description 13
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims abstract description 11
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 238000004321 preservation Methods 0.000 claims abstract description 10
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 7
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 7
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 230000001603 reducing effect Effects 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 206010049119 Emotional distress Diseases 0.000 claims description 3
- 230000009429 distress Effects 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 240000007087 Apium graveolens Species 0.000 claims description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 2
- 235000010591 Appio Nutrition 0.000 claims description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 240000007124 Brassica oleracea Species 0.000 claims description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 2
- 240000008067 Cucumis sativus Species 0.000 claims description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 2
- 244000000626 Daucus carota Species 0.000 claims description 2
- 235000002767 Daucus carota Nutrition 0.000 claims description 2
- 235000013527 bean curd Nutrition 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000015142 cultured sour cream Nutrition 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000008924 yoghurt drink Nutrition 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 8
- 244000005700 microbiome Species 0.000 abstract description 5
- 241000186000 Bifidobacterium Species 0.000 abstract description 4
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 4
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000035790 physiological processes and functions Effects 0.000 abstract description 2
- 239000006041 probiotic Substances 0.000 description 16
- 235000018291 probiotics Nutrition 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 13
- 230000000529 probiotic effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 241001608472 Bifidobacterium longum Species 0.000 description 7
- 229940009291 bifidobacterium longum Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000723382 Corylus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- -1 compound polysaccharide Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biology, and particularly relates to an animal bifidobacterium lactis BX-186 strain for relieving adverse effects of semaglutin. The classification name of the bifidobacterium animalis subspecies BX-186 provided by the invention is as follows: bifidobacterium animalis subsp. Bifidobacterium animalis lactis, deposit unit: china general microbiological culture Collection center, accession number: CGMCC No.27837, preservation time: 2023, 7 and 7. The animal bifidobacterium lactosub-species BX-186 provided by the invention can influence the metabolic activity and physiological functions of intestinal microorganisms by directly interacting with intestinal flora, restore the balance of the intestinal flora, relieve gastrointestinal discomfort symptoms caused by the semeglutide, such as nausea, vomiting, diarrhea and the like, reduce the weight and the glycosylated hemoglobin HbA1c content in blood, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to an animal bifidobacterium lactis BX-186 strain for relieving adverse effects of semaglutin.
Background
The semaglutin is a human glucagon-like peptide-1 (GLP-1) analogue produced by using saccharomyces cerevisiae cells through a gene recombination technology, and inhibits the release of glucagon which can raise blood sugar. The research shows that the medicine can regulate blood sugar, promote human body's sensitivity to insulin, raise satiety after meal, slow gastric emptying and inhibit appetite, so as to reduce body weight. Moreover, since the us FDA officially approved semaglutinin for the treatment of simple obesity in month 2021, researches show that semaglutinin can reduce the weight of non-diabetic simple fat friends by about 15% and has good safety once 2.4mg per week, so that semaglutinin plays an important role in reducing the weight. However, semaglutin has some side effects on the body, mainly including gastrointestinal reactions: such as nausea and vomiting, some of which are accompanied by diarrhea and constipation.
Bifidobacterium is a gram positive, motionless, rod-shaped bacterial genus with one end sometimes bifurcated and strictly anaerobic, and widely exists in the digestive tract, vagina, oral cavity and other habitats of humans and animals, and animal experiments find that a plurality of strains in Bifidobacterium (such as Bifidobacterium longum, bifidobacterium infantis, bifidobacterium animalis and the like) can improve host glucose tolerance.
The Chinese patent CN116376740A discloses a bifidobacterium longum with blood sugar reducing effect and application thereof, wherein the bifidobacterium longum is named WH2270, and the microorganism classification is named bifidobacterium longum subspecies Bifidobacterium longum subsp Longum; the microorganism strain is preserved in the Guangdong province center for 10 months and 18 days in 2022, the preservation address is No. 100 in martyr of Guangzhou City, and the preservation number is GDMCC No:62900 the bifidobacterium longum subspecies of the invention can improve the abundance of beneficial bacteria in intestinal tracts, can improve the content of short chain fatty acids in intestinal tracts, has excellent hypoglycemic effect, is separated from healthy infant feces, has no toxic genes, has no toxic or side effects in animal evaluation, is sensitive to various antibiotics, and has certain advantages compared with the traditional medicines for treating glycolipid metabolic disorders at present.
The Chinese another invention patent CN115804454A discloses a probiotic composition, a nutritional composition and application thereof, wherein the probiotic composition contains bifidobacterium lactis, bifidobacterium bifidum, bifidobacterium animalis, bifidobacterium longum, lactobacillus rhamnosus, lactobacillus casei, lactobacillus paracasei, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus acidophilus and streptococcus thermophilus, and the probiotic composition promotes metabolism of probiotics in human intestinal tracts by effectively compounding prebiotics such as compound polysaccharide and specific kinds of proteins and the like of various probiotics, can help inhibit weight gain and even reduce weight, regulate blood sugar and blood fat, and has the effects of resisting oxidation and aging and improving skin condition.
Probiotics have been allowed for clinical treatment of many diseases and are generally defined as a group of active microorganisms that regulate and improve the intestinal flora when ingested in sufficient amounts from the diet, yielding clear benefits for human health. However, the strain is not disclosed in the prior art, so that side effects caused by the semaglutin can be relieved, and the probiotics have the effect of regulating intestinal flora, so that the relieving effect of the probiotics on adverse reactions of the semaglutin is a possible break.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides the bifidobacterium animalis subspecies BX-186 for relieving the adverse effects of the semeglutide, and can reduce the weight and the HbA1c content of glycosylated hemoglobin in blood.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
An animal bifidobacterium lactis subspecies BX-186 for alleviating the adverse effects of semaglutin, wherein the animal bifidobacterium lactis subspecies BX-186 are classified and named as follows: bifidobacterium animalis subsp. Bifidobacterium animalis lactis, deposit unit: china general microbiological culture Collection center, accession number: CGMCC No.27837, preservation time: 2023, 7, deposit address: the institute of microbiology, national academy of sciences, china, the area North Star, west way 1, 3, beijing, chaoyang.
The invention also provides a product for preventing, alleviating and/or treating adverse effects of semaglutin, the product comprising bifidobacterium animalis subspecies BX-186 and/or fermentation metabolites of bifidobacterium animalis subspecies BX-186.
Preferably, the adverse effect is a gastrointestinal discomfort symptom including diarrhea, vomiting, and nausea.
The invention also provides a product for reducing the glycosylated hemoglobin content in blood, which comprises bifidobacterium animalis subspecies BX-186 and/or fermentation metabolites of bifidobacterium animalis subspecies BX-186.
The invention also provides a weight-reducing product comprising bifidobacterium animalis subspecies BX-186 and/or a fermentation metabolite of bifidobacterium animalis subspecies BX-186.
Preferably, the daily intake of bifidobacterium subspecies BX-186 is not less than 1.0X10 6 CFU/d.
Preferably, the product is a food, a pharmaceutical or a health product.
Preferably, the food product comprises a dairy product, a soy product or a fruit and vegetable product.
Preferably, the dairy product comprises fermented milk, sour milk beverage, sour cream or cheese.
Preferably, the soy product comprises soy milk, fermented bean curd, fermented soya beans or soy sauce.
Preferably, the fruit and vegetable product comprises cucumber, carrot, beet, celery or cabbage product.
Preferably, the pharmaceutical product comprises pharmaceutical excipients.
Preferably, the pharmaceutical excipients include at least one of fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents which are generally used in pharmacy.
Preferably, the pharmaceutical product is in the form of a tablet, powder, capsule or granule.
The invention also provides application of the bifidobacterium animalis subspecies BX-186 in preparing any one of the following products (1) - (3):
(1) A product for preventing, alleviating and/or treating adverse effects of semaglutin, which adverse effects are gastrointestinal distress symptoms including diarrhea, vomiting and nausea;
(2) A weight-loss product;
(3) A product for reducing the glycosylated hemoglobin content in blood.
Compared with the prior art, the invention has the following beneficial effects:
The bifidobacterium animalis subspecies BX-186 provided by the invention can influence the metabolic activity and physiological functions of intestinal microorganisms by directly interacting with intestinal flora, restore the balance of the intestinal flora, relieve gastrointestinal discomfort symptoms (including nausea, vomiting, diarrhea and the like) caused by the semeglutide, reduce the weight and the glycosylated hemoglobin HbA1c content in blood, and have wide application prospects.
Description of biological preservation
The classification of bifidobacterium animalis subspecies BX-186 for alleviating the adverse effects of semaglutin is named as follows: bifidobacterium animalis subsp. Bifidobacterium animalis lactis; preservation unit: china general microbiological culture Collection center, which is called CGMCC for short; preservation number: CGMCC No.27837; preservation time: 2023, 7; preservation address: the institute of microbiology, national academy of sciences, of China, the area North Star, west way 1, 3, of the Korean area of Beijing; the detection result of the strain is survival.
Drawings
FIG. 1 shows the HbA1c content of glycosylated hemoglobin in blood of 4 groups of subjects.
Detailed Description
The invention is further described below in conjunction with specific embodiments, and advantages and features of the invention will be apparent from the description. These examples are merely exemplary and are not intended to limit the scope of the invention in any way. The methods, ingredients and amounts referred to in the examples below, unless otherwise indicated, are conventional methods known to those skilled in the art. The raw materials used in the invention are all common commercial products, wherein bifidobacterium animalis subspecies Bb-12 are purchased from Corylus Hansen; soytone, available from Angel Yeast Co., ltd; yeast peptone, available from Angel Yeast Co., ltd; semaglutin, available from Shanghai Sail Biotech.
Example 1
The bifidobacterium animalis subspecies BX-186 bacterial powder is prepared according to the conventional bacterial powder preparation process, and the preparation process comprises the following steps:
1. Activating strains: inoculating the bifidobacterium animalis subspecies BX-186 strain frozen at-80 ℃ into corresponding liquid culture media after sterilization at 121 ℃ for 15min, and performing anaerobic culture at 37 ℃ for 18-24h, thus performing subculture for 1-2 times to obtain activated strains; the bifidobacterium animalis subspecies BX-186 is cultivated by adopting a lactobacillus optimized culture medium.
2. Preparing bacterial liquid: inoculating each strain activated in the step (1) into a lactobacillus optimized culture medium, and stopping anaerobic culture at 37 ℃ until the pH value is 4.5-4.8 to obtain seed liquid.
The composition of the optimized lactobacillus culture medium is as follows: 23.5Kg of sucrose, 12.0Kg of lactose, 15.0Kg of soytone, 5.0Kg of yeast powder, 12Kg of yeast peptone, 21.0Kg of Na 2HPO3, 2.0Kg of citric acid, 0.3Kg of MgSO 4·7H2O 0.6Kg,MnSO4·5H2 O, 1.0Kg of Tween-80, 0.3Kg of L-cysteine hydrochloride and distilled water to 1000L.
3. Inoculating and fermenting: inoculating the seed solution in the step (2) into the lactobacillus optimized culture medium prepared in the step (2) according to 1 per mill, and fermenting for 18 hours under controlled fermentation conditions.
The fermentation conditions are controlled as follows: culturing at 30deg.C in the early stage of fermentation, and naturally fermenting until pH is 5.0; then adjusting the fermentation temperature to 37 ℃ for constant temperature culture, controlling the pH value to be 6.0, and keeping anaerobic fermentation. The pH was maintained at 6.0 during this step by adding a neutralizing agent, which is NaOH.
The anaerobic fermentation condition is maintained in the following manner: by introducing nitrogen once every two hours.
4. Terminating fermentation: when the acid production of the thalli is stopped, the fermentation is stopped, the high-density fermentation liquor of the strain is obtained, and the viable count of the fermentation liquor reaches more than 2 multiplied by 10 10 CFU/mL. Wherein, whether acid production is stopped is judged by no more decrease in pH and stop of the addition of the neutralizing agent.
5. And (3) freeze drying: a. and (3) concentration of thalli: concentrating the high-density fermentation broth by 12000g centrifugation;
b. and (3) adding a protective agent: adding 5 times of protective agent solution in the bacterial concentrate; the composition of the protectant solution is as follows: 15Kg of skim milk, 12Kg of lactose, 1Kg of vitamin C, 1Kg of sodium glutamate and 1000L of distilled water;
c. And (3) drying: freeze-drying the bacterial suspension added with the protective agent to obtain freeze-dried bacterial powder, mixing bacterial powder of each strain according to a proportion (colony forming unit number proportion), and controlling the total number of viable bacteria in the mixed bacterial powder to be more than 2.0X10 11 CFU/g.
The viable count of the bifidobacterium animalis subspecies BX-186 bacteria powder prepared in the embodiment reaches 2000 hundred million/g-5000 hundred million/g.
Comparative example 1
The preparation process of the bifidobacterium animalis subspecies Bb-12 bacterial powder is the same as that of the embodiment 1, and the viable count of the bifidobacterium animalis subspecies Bb-12 bacterial powder is 2000 hundred million/g-5000 hundred million/g.
Experimental example
1. Experimental objects
120 Adult volunteers, including 60 men and 60 women, were enrolled, each with BMI either greater than or equal to 27kg/m 2 or greater than or equal to 30kg/m 2. All subjects were first run in for 20 weeks of semaglutin, and only subjects tolerating a 2.4mg dose at week 20 could run the randomization experiment. For intolerance to 2.4mg of semaglutin and for some personal reasons, 20 were excluded and eventually 100 subjects participated in the experiment.
2. Experimental method
2.1 Grouping
100 Volunteers were randomly divided into 4 groups of 25 persons each. The 4 groups are as follows: probiotic group: bifidobacterium animalis subspecies BX-186 flour + semeglutide; comparison group: bifidobacterium animalis subspecies Bb-12 bacteria powder and semaglutin; control group: semaglutin; placebo group: placebo (physiological saline).
2.2 Methods of administration
The intake dose of the bifidobacterium animalis subspecies BX-186 bacterial powder and the bifidobacterium animalis subspecies Bb-12 bacterial powder is 300 hundred million CFU/d per person, the injection dose of the semeglutide is 32.4mg/d per person, and the injection dose of the placebo is 32.4mg/d per person.
2.3 Index detection
Each group was subjected to a questionnaire assessment of body weight, adverse gastrointestinal reactions (nausea, diarrhea, vomiting) and blood samples from the subjects were collected for the measurement of glycosylated hemoglobin after baseline (baseline) and 6 months of intervention to assess the modulating effect of bifidobacterium animalis subspecies BX-186 on adverse reactions in the subjects caused by semaglutinin.
3. Experimental results
3.1 Subject weight analysis
The body weight of the subjects was assessed during the baseline period and after 6 months of intervention. The results are shown in table 1, with the probiotic, control and control groups, the body weight of the subjects was significantly reduced after 6 months of intervention compared to the placebo group, and the magnitude of the probiotic reduction was higher than the other groups. Indicating that the intervention of bifidobacterium animalis subspecies lactis BX-186 can reduce the weight more effectively.
Weight index of Table 14 group of subjects
3.2 Analysis of nausea Condition in a subject
Subjects were subjected to a nausea condition questionnaire analysis at baseline and 6 months after the intervention treatment. The results are shown in table 2, with the probiotic group, after 6 months of intervention, the nausea of the subjects was significantly improved compared to the control and control groups, and not significantly different from the placebo group. Indicating that the intervention of bifidobacterium animalis subspecies lactis BX-186 can relieve nausea symptoms caused by injection of semaglutin.
Table 24 nausea index status for group of subjects
3.3 Analysis of diarrhea status in subjects
Subjects were subjected to a diarrhea condition questionnaire analysis at baseline and 6 months after the intervention treatment. The results are shown in table 3, with the probiotic group, after 6 months of intervention, the diarrhea status of the subjects was significantly improved compared to the control and control groups, and no significant differences from the placebo group. Indicating that the intervention of bifidobacterium animalis subspecies lactis BX-186 can relieve diarrhea symptoms caused by injection of semaglutin.
Diarrhea index status of Table 34 group of subjects
3.4 Analysis of vomiting status in subjects
Subjects were subjected to a vomiting status questionnaire analysis at baseline and 6 months after intervention treatment. The results are shown in table 4, with the probiotic group, after 6 months of intervention, the vomiting status of the subjects was significantly improved compared to the control and control groups, and not significantly different from the placebo group. The intervention of bifidobacterium animalis subspecies BX-186 can effectively relieve the vomiting symptoms caused by the injection of the semaglutin.
Vomit index status of Table 44 group of subjects
3.5 HbA1c indicator analysis of glycosylated hemoglobin of subject
Blood samples from subjects were subjected to a volume analysis at baseline and 6 months after the intervention treatment. The results are shown in figure 1, with the HbA1c content in the blood of the subjects of the probiotic group, the control group and the control group significantly reduced compared to the placebo group, and the probiotic group most significantly reduced after 6 months of intervention. Indicating that the intervention of bifidobacterium animalis subspecies lactis BX-186 can effectively reduce HbA1c content in blood of a subject.
In conclusion, the intervention of the bifidobacterium animalis subspecies BX-186 can effectively relieve gastrointestinal discomfort symptoms (including nausea, vomiting and diarrhea) of a subject caused by the semaglutinin, and can achieve the effects of reducing the weight and the HbA1c content of glycosylated hemoglobin in blood.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. An animal bifidobacterium lactis subspecies BX-186 for alleviating the adverse effects of semaglutin, which is characterized in that the classification of the animal bifidobacterium lactis subspecies BX-186 is named as: bifidobacterium animalis subsp. Bifidobacterium animalis lactis, deposit unit: china general microbiological culture Collection center, accession number: CGMCC No.27837, preservation time: 2023, 7 and 7.
2. A product for preventing, alleviating and/or treating adverse effects of semaglutin, characterized in that said product comprises bifidobacterium animalis subspecies BX-186 and/or a fermentation metabolite of said bifidobacterium animalis subspecies BX-186 according to claim 1.
3. The product of claim 2, wherein the adverse effect is a gastrointestinal distress symptom including diarrhea, vomiting, and nausea.
4. A product for reducing the glycosylated hemoglobin content of blood, characterized in that the product comprises bifidobacterium animalis subspecies BX-186 and/or a fermentation metabolite of bifidobacterium animalis subspecies BX-186 according to claim 1.
5. A weight-reducing product, characterized in that it comprises bifidobacterium animalis subspecies BX-186 and/or a fermentation metabolite of bifidobacterium animalis subspecies BX-186 according to claim 1.
6. The product according to any one of claims 2-5, wherein the product is a food, pharmaceutical or health product.
7. The product of claim 6, wherein the food product comprises a dairy product, a soy product, or a fruit and vegetable product, the dairy product comprising fermented milk, yogurt drink, sour cream, or cheese; the bean product comprises soybean milk, fermented bean curd, fermented soybean or soybean paste; the fruit and vegetable product comprises cucumber, carrot, beet, celery or cabbage product.
8. The product of claim 6, wherein the pharmaceutical product comprises a pharmaceutical excipient and the pharmaceutical product is in the form of a tablet, powder, capsule or granule.
9. The product of claim 8, wherein the pharmaceutical excipients comprise at least one of fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents commonly used in pharmacy.
10. Use of bifidobacterium animalis subspecies BX-186 as claimed in claim 1 in the manufacture of any one of the following products (1) - (3), (1) products for preventing, alleviating and/or treating adverse effects of semaglutin, said adverse effects being gastrointestinal distress symptoms including diarrhea, vomiting and nausea; (2) a weight-loss product; (3) a product for reducing the glycosylated hemoglobin content in blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410307103.6A CN118516248A (en) | 2024-03-18 | 2024-03-18 | Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410307103.6A CN118516248A (en) | 2024-03-18 | 2024-03-18 | Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118516248A true CN118516248A (en) | 2024-08-20 |
Family
ID=92282978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410307103.6A Pending CN118516248A (en) | 2024-03-18 | 2024-03-18 | Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118516248A (en) |
-
2024
- 2024-03-18 CN CN202410307103.6A patent/CN118516248A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105105145B (en) | Lactobacillus plantarum and application thereof in preparation of functional food for reducing blood sugar and blood fat | |
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| CN114854643B (en) | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof | |
| TWI241912B (en) | Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
| US20210275612A1 (en) | Method for alleviating inflammation-related disorder | |
| CN102274245B (en) | Novel lactacidophilus, composition thereof and use thereof in preparation of medicines for relieving diabetes mellitus and complications | |
| CN112075638A (en) | Food compositions and pharmaceutical compositions comprising a hypoglycemic lactic acid bacterial strain | |
| TWI739495B (en) | Composition for promoting defecation and use therefor | |
| CN113005067B (en) | Multifunctional composite probiotic preparation and preparation method thereof | |
| CN116555076B (en) | Bifidobacterium longum subspecies longum MY1 and application thereof in preparation of food and medicine for relaxing bowels and protecting intestines | |
| KR102543494B1 (en) | Novel probiotics and use thereof | |
| CN114848684A (en) | Composite probiotic composition with obvious effect of improving hyperlipidemia | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN113755370B (en) | Application of lactobacillus acidophilus LA85 in preparation of hypolipidemic drugs or health-care foods | |
| CN116891810A (en) | Probiotic composition with blood sugar reducing effect and probiotic prebiotic composite preparation | |
| CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
| CN117286045B (en) | Bifidobacterium longum subspecies longum KS2 and application thereof in preparation of anti-aging medicines | |
| CN111035661A (en) | Application of lactobacillus plantarum | |
| CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN114984065B (en) | Probiotic composition for improving immunity and preparation method thereof | |
| US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
| CN114908004A (en) | Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof | |
| CN118516248A (en) | Bifidobacterium animalis subspecies BX-186 for relieving adverse effects of semeglutide | |
| CN113355374A (en) | Method for synthesizing B vitamins by fermenting lactobacillus paracasei ET-22 and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |